Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04819854 | Single and Multiple Ascending Dose Study With EP395 | completed | Phase 1 | 78 | EpiEndo PharmaceuticalsINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02211755 | Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies |
| completed |
| Phase 1 |
| 134 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Apr 28, 2026 |
| clinicaltrials |
| NCT04981795 | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL(realMIND) | completed | — | 102 | Incyte CorporationINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02783625 | Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas | completed | Phase 1 | 114 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT05388123 | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | completed | Phase 2 | 15 | Scripps HealthOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02316106 | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma | completed | Phase 2 | 123 | Janssen Research & Development, LLCINDUSTRY | 11 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03298321 | Action of the Vidaza on the Atrial Fibrillation(AVIFA) | completed | — | 1 | Hospices Civils de LyonOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03593018 | Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL | completed | Phase 3 | 86 | The Lymphoma Academic Research OrganisationOTHER | 5 | Apr 23, 2026 | clinicaltrials |
| NCT02433795 | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | completed | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01816971 | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 76 | University of ChicagoOTHER | 2 | Apr 21, 2026 | clinicaltrials |
| NCT01853358 | Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation(DLI-NK) | completed | Phase 1 | 17 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02320656 | Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015(HEMATO-BIO) | completed | N/A | 650 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02553447 | Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency | completed | N/A | 197 | University of NebraskaOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03578367 | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. | completed | Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 21, 2026 | clinicaltrials |
| NCT03595813 | Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy(IMMUNO-SUP) | completed | N/A | 135 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03623373 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 13 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05858593 | Positive Youth Development in the Metaverse | completed | N/A | 32 | University of GeorgiaOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03777306 | The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma | completed | N/A | 85 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04625413 | A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists(UR-GOAL 1) | completed | N/A | 15 | University of RochesterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05189093 | Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma | completed | Phase 1 / Phase 2 | 48 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03341520 | Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma(GAZAI) | completed | Phase 2 | 89 | Heidelberg UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04996160 | Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 2 | Tanja Andrea GruberOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04392960 | Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis | completed | N/A | 30 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04641910 | Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia(FLAMVAL) | completed | — | 201 | Nantes University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06418750 | Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study(DELICATESSE) | completed | N/A | 20 | Nantes University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT03935282 | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors(AH-HA) | completed | N/A | 645 | Wake Forest University Health SciencesOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05164016 | Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients | completed | — | 21 | St. Jude Children's Research HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04557150 | A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) | completed | Phase 1 | 225 | Hoffmann-La RocheINDUSTRY | 9 | Apr 13, 2026 | clinicaltrials |
| NCT05106374 | Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer | completed | — | 182 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03466294 | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | completed | Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03984097 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | completed | Phase 1 | 50 | TakedaINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04433156 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | completed | Phase 2 | 26 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01241734 | Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL(RICER) | completed | Phase 1 / Phase 2 | 18 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01453101 | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma(Flu-Mel-Vel) | completed | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02405364 | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction(IFM-CRd) | completed | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04081779 | Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study | completed | N/A | 261 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M) | completed | Phase 3 | 112 | AbbVieINDUSTRY | 19 | Apr 8, 2026 | clinicaltrials |
| NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL(DEB) | completed | Phase 3 | 423 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04488354 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | completed | Phase 1 | 16 | Calibr, a division of Scripps ResearchOTHER | 1 | Apr 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2026source: clinicaltrials